Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
- Written by PR Newswire
YANTAI, China, Dec. 27, 2023 /PRNewswire/ -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA): one is BA1105, an innovative antibody; and the other is BA1301, an innovative...
Read more: Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA














